Half-Life Fundamentals
Peptide half-life determines dosing frequency and duration of effects. Understanding the factors that control peptide stability helps optimize research protocols and interpret study results.
Enzymatic Degradation
Peptidases and proteases are the primary factors limiting peptide half-life. These enzymes cleave specific amino acid sequences, rapidly breaking down natural peptides like gonadorelin (2-4 minute half-life) while modified peptides like CJC-1295 with DAC resist degradation for days.
Chemical Modifications
Research peptides often include modifications to extend half-life. D-amino acids resist enzymatic cleavage. Cyclization protects vulnerable sequences. PEGylation and DAC (Drug Affinity Complex) modifications can extend half-life from minutes to days.
Tissue Distribution
Peptides with high tissue binding or specific receptor interactions may have longer apparent half-lives at target sites despite rapid blood clearance. This explains why some peptides show prolonged effects beyond their measured plasma half-life.
Route of Administration
Subcutaneous injection typically provides longer effective half-life than intravenous due to slower absorption. Oral administration faces additional degradation from digestive enzymes, often requiring enteric protection or absorption enhancers.
Practical Applications
Short half-life peptides (under 1 hour) typically require multiple daily doses. Medium half-life compounds (4-12 hours) may work with once or twice daily dosing. Long half-life peptides (days) enable weekly administration but require careful monitoring for accumulation effects.
This information is for research purposes only and does not constitute medical advice. Half-life data should guide research protocol development under qualified supervision.